Company Profile
PolyPid Stock Price, News & Catalysts
- Ticker:
- PYPD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel
Stock performance
4.77 USD (+0.63%)
Close
Last updated: August 17, 2026
93.4M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, PYPD closed up 0.63% at $4.77. No new same-company headline was identified in the current news window.
Company overview
Local Controlled-Release Therapeutics
PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden.
PLEX Technology
The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over days or weeks.
D-PLEX100
D-PLEX100 delivers doxycycline locally after abdominal colorectal surgery to prevent surgical-site infections. Its NDA is supported by the pivotal Phase 3 SHIELD II study, which met its primary and key secondary endpoints.
Azurity Partnership
Azurity Pharmaceuticals holds U.S. and Canadian commercialization rights to D-PLEX100. PolyPid retains eligibility for development and commercial milestones plus tiered royalties.
Future catalysts
- FDA action on the D-PLEX100 NDA by the November 28, 2026 PDUFA goal date.
- Potential U.S. commercial launch of D-PLEX100 by Azurity in early 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PolyPid (PYPD)?
PolyPid (PYPD) most recently closed at 4.77 USD, a +0.63% move versus the previous session.
What is the market cap of PolyPid (PYPD)?
PolyPid currently has a market capitalization of 93.4M USD on BioPharmSignal.
What does PolyPid do?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over...
On which exchange is PYPD stock listed?
PolyPid (PYPD) is associated with NASDAQ, Israel, Biopharma.
What is Local?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site.
Which conditions is PolyPid targeting with Local?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control local release over...
How does PolyPid describe recent progress with Local?
FDA action on the D-PLEX100 NDA by the November 28, 2026 PDUFA goal date. Potential U.S. commercial launch of D-PLEX100 by Azurity in early 2027, subject to approval.
What is Controlled-Release?
Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site.